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Abstract  Article Info 
Introduction: Nasopharyngeal carcinoma (NPC) is one kind of cancer that is the most common type of head 
and neck malignancy, arising from the posterior and lateral parts of the nasopharynx especially from torus 
tubarius or pharyngeal recess or the other name is Rosenmüller fossa. This shows significant differences from 
other head and neck cancers, clinical behavior, cause, epidemiology, treatment, as well as prognosis. Clinical 
trials of COVID-19 vaccines with better follow-up will provide useful data on vaccine advantages in patients 
receiving cancer treatment, due to the absence of complete data to determine the relationship between active 
oncology treatment and the power to induce immunity to COVID-19 using the vaccine. 
Discussion: The primary aim of vaccines is to produce stimulation by the antigen we desire in the presence of 
sufficient infection to elicit memory immunity with tolerable protection. Due to the increasing frailty of cancer 
patients with infection as well as deaths from COVID-19, there is an urgent need to vaccinate patients with 
COVID-19 cancer. Various considerations for the protection and benefits that are expected to have an effect 
with treatment due to their standart management and changes in the immune system of patients with 
malignancies. 
Conclusion The COVID-19 vaccine, granted approved or permitted, will be considered the basic of prevention 
of this COVID-19 pandemic for patients with nasopharyngeal carcinoma. There are advantages and 
disadvantages about Covid-19 vaccine. Then, a quality direction on clinical trials of patients with cancer and 
COVID-19 vaccines becomes very attractive. Finally, comprehensive oncological care requires cancer patients 
to be prioritized for the COVID-19 vaccine. 
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1.   INTRODUCTION 
Nasopharyngeal carcinoma (NPC) is one kind of cancer that is the most 
common type of head and neck malignancy, arising from the posterior and lateral 
parts of the nasopharynx especially from torus tubarius or pharyngeal recess or 
the other name is Rosenmüller fossa. This shows significant differences from 
other head and neck cancers, clinical behavior, cause, epidemiology, treatment, 
as well as prognosis. A sum of morbidities was about 129,000 and mortalities 
were 73,000 reported in 2018 in the world. And rarely found in the Europe or 
USA. Nasopharyngeal carcinoma is endemic in North Africa, Southeast Asia, 
and Arctic, has a relationship with viral infection of EBV (Epstein–Barr virus). 
According to classification of World Health Organization—WHO, 
Nasopharyngeal cancer with the kind of histopathology undifferentiated 
nonkeratinizing squamous cell carcinoma (type III) is the most dominant [1, 3].  
The COVID-19 pandemic due to viral infection of agent SARS CoV-2 
(Severe acute respiratory syndrome coronavirus-2) with the primary pronounced 
outbreak in China in 2019 back then. It was found into an excessive quantity 
withinside the mucosa of the upper respiratory tract [4]. An increased risk of 
contamination is affecting on all head and neck surgeons when giving treatment 
to the patients with Nasopharyngeal Carcinoma. The public is concern over the 
increase in the equipment of personal protective for the health workers (doctors, 
nurses and care givers) as the number of confirmed COVID-19 cases grows a lot 
higher [5]. 
Until now, information about the strength of COVID-19 vaccination in 
patients with nasopharyngeal carcinoma is very limited. On the 43,540 subjects 
was going through vaccine trial in of the BNT162b2 mRNA, 3.7% had been 
pronounced to have malignancy, with 5 patients developed COVID-19 disease 
one in the vaccine arm and four in the placebo arm; ref. 30 was at the time of 
reporting.  Other trials on the COVID-19 vaccine with higher follow-up will 
display beneficial records on the advantages of the vaccines in patients who 
received different cancer management, however, having not complete 
information to know the relations about management of active malignancy and 
the strength to raise the immunity against COVID-19 using vaccine. [6]. It is 
shown that COVID-19 vaccines could leave higher levels to neutralize the 
antibodies than the infection of SARS-CoV2 in a large number of subjects [7, 8]. 
It will be very important to offer priority vaccination for patients with cancer who 
are receiving the chemotherapy which is cytotoxic. Patients with cancers have 
not very strong immune responses to COVID-19 on current data [9].   
 
2.    MAIN TEXT 
Immunity of humoral and immunity of cell mediated are immunity to 
guard ourselves of viral infections. Humoral immunity is immunity through 
B lymphocytes that producing antibody and may also additionally neutralize 
virus through binding the viral and stopping the access into host cells. 
Immunity of Cell mediated consists of CD8+ cytotoxic T lymphocytes and 
macrophages, which delete cells which is infected by the virus. The 
generation of notably efective antibody responses and memory was help by 
the CD4+ T lymphocytes which support to make the B and CD8+ T cells 
become active. The immunity of opsonizing and cell-mediated is helped by 
the IgG antibody CD4+ helper T cell subsets consist of  T1, and T2 which 
will enables Immunoglobulin E antibody and allergic-kind inflammation. 
On repeat infection, the host’s immune responses will be recalled by 
antigen-specific memory B and T cells will stay persist. 
Those protecting immune responses are began out via way of means of 
expert antigen- presenting cells (APC) in viral infections, which is include 
dendritic cells, it is the cell which process, capture, and show withinside the 
secondary lymphoid tissues there are the peptides of virus to the molecules 
of MHC to prime naïve antigen-specific T cells. Active T cell priming 
frequently calls for extra stimulatory cytokines also co-stimulatory 
molecules. The primary aim of vaccines is to produce stimulation by the 
antigen we desire in the presence of sufficient infection to elicit memory 
immunity with tolerable protection. Qualified immunogenic vaccines 
require adjuvants and/or a "high-boost" method of multiple doses to produce 
higher immune responses [10]. 
 
2.1 The Advantages and Disadvantages of COVID-19 Vaccine  
Until now, the rremarkable of the 66 COVID-19 vaccines currently in 
clinical trials, 10 vaccines are permitted with limited vaccine use. The table 
below shows some of the strength and weakness of the Covid-19 vaccine 
(Table 1) [11, 12]. 








Picture 1. Table of the strength and weakness of Covid-19 vaccine [15]. 
 
2.2.  Implications for Patient with Nasopharyngeal Carcinoma  
It is found in patients with malignancy, they are at high risk of 
developing severe disease due to COVID-19 [29]. From a study conducted 
in the United States about 73 million subjects, and found that 273,000 
patients were diagnosed with malignancy last year and 16,570 patients 
diagnosed with COVID-19, patients with malignancy have a very high risk 
of being infected with COVID-19. -19 ((aOR ) adjusted odds ratio of 7;). In 
this case, the highest chance of infection was found for patients with blood 
malignancies, namely lung cancer (aOR 7.7), non-Hodgkin's lymphoma 
(aOR 8.5) and leukemia (aOR 12.2), The mortality rate was also increase in 
patients with malignancies which could increase the risk of contracting 
COVID-19. Conluded, patients with malignancies and COVID-19 had a 
higher risk of death (14.9%) than patients with COVID-19 without 
malignancies (5.3 %) and patients with malignancies without COVID-19 
(4.0%) [13]. Also, in patients who had a diagnosis of hematological cancer 
within the last 5 years, there was an estimated 2.5-fold increased risk of 
death, and for other malignancies, it was at least 1.2-fold [14]. Due to the 
increasing frailty of cancer patients with infection as well as deaths from 
COVID-19, there is an urgent need to vaccinate patients with COVID-19 
cancer. Various considerations for the protection and benefits that are 
expected to have an effect with treatment due to their standard management 
and changes in the immune system of patients with malignancies.  
 
2.3 Review for patients given Cytotoxic Chemotherapies 
Chemotherapy has an effect on DNA synthesis, DNA replication, and 
the development of the cell cycle. The existence of the process of 
Proliferation of Lymphocytes takes place rapidly as part of the activation 
which is then reduced due to chemotherapy [17]. Therefore, an incomplete 
reduction and the immune response can still be elicited to be vaccinated 
while undergoing this kind of therapy. In patients with a diagnosis of acute 
lymphoblastic leukemia, where chemotherapy given to these patients 
directly affects the immune system, after vaccination, an immune response 
can still be elicited, ranging from 10% and 27% of patients has 
immunization with vaccine of meningococcal and vaccine of hepatitis B 
subunit. , up to 100% of administered patients are immunized with tetanus 
vaccine and diphtheria toxoid [16, 19]. In one study examining the 
association between malignancy inactivation and influenza vaccine, it was 
found that 10-42% of patients with hematological cancer had a response to 
one dose of influenza vaccine and an additional response to a second dose 
(18,20,26,27). Better patient response was seen in patients with solid 
neoplasms on therapy [21] 81% of patients with breast carcinoma and other 
solid tumors such as nasopharyngeal carcinoma [23,25] at least 78% of 
patients with lung carcinoma who were given chemotherapy had mild 
immunologic impairment to medium. When given about cycles of 
chemotherapy for breast cancer or lung carcinoma or and nasopharyngeal 
cancer relative to the last cycle, although estimates of optimal days vary 
[28]. Vaccinations were tolerated in this study. Judging from the IDSA 
(Infectious Diseases Society of America) and ECIL (The European 
Conference on Infections in Leukemia) which suggest annually an 
immunogen with an inactivated influenza vaccine-except during intensive 
medical assistance provided a poor response may be found, but affordable 
given the nature of the disease. seasonality of influenza [29, 30]. The 
monetary unit vaccination of diplococcus and viral hepatitis may be useful 
even during the course of therapy [31, 32]. Titers may provide assistance in 
assessing propensity for revaccination [33]. The number of doses or boosters 
used to promote an immunogenicity of vaccines, hepatitis B subunits, 
pneumococcal polysaccharides, and inactivated influenza [34]. Indeed, with 
one exception during periods of intensive cytotoxic chemotherapy, patients 
undergoing chemotherapy are expected to produce a protective response 
with COVID-19 vaccination. 
 
2.4 Review for patients given Radiotherapy 
Radiotherapy is the treatment needed for people with cancer in the healing 
or palliative phase. Until now we know that the effects of radiation will 
affect a large part of the human body and can affect the bone marrow. It is 
very infrequent that radiotherapy has a valuable effect on immunity to a 
factor for which vaccination is no longer allowed. The patient's preferred 
body condition for radiation to enhance the formation of immune cells is in 
terms of how much total body radiation (TBI) is given to suppress the 
marrow previous to transplantation of stem cell or some other condition in 
which the patient receives spine or lymph node irradiation. Indeed, patients 
were going through radiotherapy should be allowed to have a protective 
immune response to the COVID-19 vaccine. 
 
3.   CONCLUSION 
The COVID-19 vaccine, granted approved or permitted, will be 
considered the basic of prevention of this COVID-19 pandemic for patients 
with nasopharyngeal carcinoma. There are advantages and disadvantages 
about Covid-19 vaccine. Then, a quality direction on clinical trials of 
patients with cancer and COVID-19 vaccines becomes very attractive. 
Finally, comprehensive oncological care requires cancer patients to be 
prioritized for the COVID-19 vaccine. 
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